Literature DB >> 27829990

Analysis of the effects of preservative-free tafluprost on the tear proteome.

Sebastian Funke1, Sabine Beck1, Katrin Lorenz1, Marion Kotterer1, Dominik Wolters1, Natarajan Perumal1, Norbert Pfeiffer1, Franz H Grus1.   

Abstract

The purpose of the present study was to assess the ocular surface health status in primary open angle glaucoma (POAG) patients switching from topical application of preserved latanoprost (LT) to preservative-free tafluprost (PFT) by tear proteomic monitoring. Tear fluid of POAG patients showing dry eye symptoms, using LT and switching to PFT as well as tear fluid of healthy controls has been examined. Tear proteome dynamics was monitored over 24 weeks in a first mass spectrometric explorative analysis in a small POAG patient cohort (N = 3). Longitudinal responses of candidate proteins as well as cytokines were comparatively analyzed by microarray in a larger cohort of POAG patients (N = 16) and healthy controls (N = 15). Clinical parameters including tear breakup time (TBUT) and basal Schirmer test (BST) were recorded. Distinct post-switch level alterations could be documented in POAG tear proteins (> 1000). Cellular leakage proteins, dry eye related candidates and cytokines showed predominantly level diminishment in POAG patients and approximation to the tear protein level of healthy controls in response to PFT. Tear proteins like pyruvate kinase isozymes M1/M2 or galectin 7 displayed linear tear film level decline in POAG patients (R2≥0.9; P < 0.05) distinctly converging the healthy level. Proteomic outcome fit well with improved clinical parameters, TBUT and BST. In conclusion, tear proteomic alterations indicated ocular surface recovery regarding epithelia leakage and inflammation recession. Together with improved clinical parameters the study output proposes beneficial effects of PFT glaucoma therapy.

Entities:  

Keywords:  Tear proteomics; glaucoma therapy; preservatives; tafluprost

Year:  2016        PMID: 27829990      PMCID: PMC5095299     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  71 in total

1.  Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone.

Authors:  J Shimazaki; K Hanada; Y Yagi; J Yamagami; M Ishioka; S Shimmura; K Tsubota
Journal:  Br J Ophthalmol       Date:  2000-11       Impact factor: 4.638

2.  Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension.

Authors:  Christophe Baudouin; Jean-Paul Renard; Jean-Philippe Nordmann; Philippe Denis; Yves Lachkar; Eric Sellem; Jean-François Rouland; Viviane Jeanbat; Stéphane Bouée
Journal:  Eur J Ophthalmol       Date:  2012-06-11       Impact factor: 2.597

3.  Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.

Authors:  Carl Erb; Ines Lanzl; Seid-Fatima Seidova; Friedemann Kimmich
Journal:  Adv Ther       Date:  2011-06-30       Impact factor: 3.845

4.  Postadaptational resistance to benzalkonium chloride and subsequent physicochemical modifications of Listeria monocytogenes.

Authors:  Monica S To; Stacy Favrin; Nadya Romanova; Mansel W Griffiths
Journal:  Appl Environ Microbiol       Date:  2002-11       Impact factor: 4.792

5.  Effects of antiglaucoma drugs on the ocular surface in rabbits: a fixed-combination drug versus two concomitant drugs.

Authors:  Hyun Kyung Cho; Myoung Hee Park; Jung Il Moon
Journal:  Jpn J Ophthalmol       Date:  2011-09-09       Impact factor: 2.447

6.  Longitudinal analysis of taurine induced effects on the tear proteome of contact lens wearers and dry eye patients using a RP-RP-Capillary-HPLC-MALDI TOF/TOF MS approach.

Authors:  Sebastian Funke; Diana Azimi; Dominik Wolters; Franz H Grus; Norbert Pfeiffer
Journal:  J Proteomics       Date:  2012-03-24       Impact factor: 4.044

7.  The reactivity of taurine with hypochlorous acid and its application for eye drops.

Authors:  I Koyama; K Nakamori; T Nagahama; M Ogasawara; M Nemoto
Journal:  Adv Exp Med Biol       Date:  1996       Impact factor: 2.622

8.  Alterations in the tear proteome of dry eye patients--a matter of the clinical phenotype.

Authors:  Nils Boehm; Sebastian Funke; Michaela Wiegand; Nelli Wehrwein; Norbert Pfeiffer; Franz H Grus
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-28       Impact factor: 4.799

9.  Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.

Authors:  Anastasios G P Konstas; Luciano Quaranta; Andreas Katsanos; Ivano Riva; James C Tsai; Theodoros Giannopoulos; Irini C Voudouragkaki; Eleni Paschalinou; Irene Floriani; Anna-Bettina Haidich
Journal:  Br J Ophthalmol       Date:  2013-05-16       Impact factor: 4.638

10.  Evaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cells.

Authors:  Seth P Epstein; Dongmei Chen; Penny A Asbell
Journal:  J Ocul Pharmacol Ther       Date:  2009-10       Impact factor: 2.671

View more
  5 in total

1.  Comparison of iTRAQ and SWATH in a clinical study with multiple time points.

Authors:  Antti Jylhä; Janika Nättinen; Ulla Aapola; Alexandra Mikhailova; Matti Nykter; Lei Zhou; Roger Beuerman; Hannu Uusitalo
Journal:  Clin Proteomics       Date:  2018-07-30       Impact factor: 3.988

2.  Comparative analysis of cytokine profiles of glaucomatous tears and aqueous humour reveals potential biomarkers for trabeculectomy complications.

Authors:  Éva Csősz; Eszter Deák; Noémi Tóth; Carlo Enrico Traverso; Adrienne Csutak; József Tőzsér
Journal:  FEBS Open Bio       Date:  2019-04-23       Impact factor: 2.693

3.  The use of preservatives in dry eye drops.

Authors:  Karen Walsh; Lyndon Jones
Journal:  Clin Ophthalmol       Date:  2019-08-01

Review 4.  Clinical Tear Fluid Proteomics-A Novel Tool in Glaucoma Research.

Authors:  Janika Nättinen; Ulla Aapola; Praveena Nukareddy; Hannu Uusitalo
Journal:  Int J Mol Sci       Date:  2022-07-23       Impact factor: 6.208

5.  Patient stratification in clinical glaucoma trials using the individual tear proteome.

Authors:  Janika Nättinen; Antti Jylhä; Ulla Aapola; Minna Parkkari; Alexandra Mikhailova; Roger W Beuerman; Hannu Uusitalo
Journal:  Sci Rep       Date:  2018-08-13       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.